HK Stock Market Move | TIAN CHENG HLDG(02110) plunges sharply in the afternoon with volume, dropping more than 70% to hit a new low during the trading session. Unusual activity in the stock in recent days.
Tiancheng Holdings (02110) saw a surge in trading volume and a flash crash in the afternoon, hitting a record low of 0.072 Hong Kong dollars. As of the time of writing, it has fallen by 66.79% to 0.093 Hong Kong dollars, with a turnover of 41.0523 million Hong Kong dollars.
TIAN CHENG HLDG (02110) experienced a sharp decline in the afternoon with a high trading volume, hitting a new low of 0.072 Hong Kong dollars. As of the time of writing, it has fallen by 66.79% to 0.093 Hong Kong dollars, with a trading volume of 41.0523 million Hong Kong dollars.
On the news front, on November 21st, TIAN CHENG HLDG's shareholders deposited their stocks into Yuanku Securities, with a market value of 8.88 million Hong Kong dollars, accounting for 20.00% of the total. Previously, on October 24th, there was also a stock deposit movement with a percentage of 12.8%, deposited into Yuanku Securities. TIAN CHENG HLDG announced on November 21st that they have completed the private placement of 60 million shares, raising approximately 6.93 million Hong Kong dollars in net proceeds, which will be fully used for the group's general operating funds.
Related Articles

Seize "Black Myth" GCL (GCL.US): The gaming sector's rare dark horse stock, is the next "myth" on the way?

Goldman Sachs: Expect more AI achievements to be announced and applied to Xiaomi-W(01810) ecosystem in the future. Target price is 53.5 Hong Kong dollars.

HK Stock Market Move | BIOCYTOGEN-B(02315) increased by more than 3%, licensing IDEAYA's dual-target ADC project IDE034 received FDA IND approval.
Seize "Black Myth" GCL (GCL.US): The gaming sector's rare dark horse stock, is the next "myth" on the way?

Goldman Sachs: Expect more AI achievements to be announced and applied to Xiaomi-W(01810) ecosystem in the future. Target price is 53.5 Hong Kong dollars.

HK Stock Market Move | BIOCYTOGEN-B(02315) increased by more than 3%, licensing IDEAYA's dual-target ADC project IDE034 received FDA IND approval.






